Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Feb;80(2):131-146.
doi: 10.1007/s40265-019-01235-5.

Poly (ADP-ribose) Polymerase Inhibition in Patients with Breast Cancer and BRCA 1 and 2 Mutations

Yolanda Jerez  1   2 , Ivan Márquez-Rodas  1   2 , Inmaculada Aparicio  1 , Manuel Alva  1 , Miguel Martín  3   4 , Sara López-Tarruella  1   2
Affiliations
Review

Poly (ADP-ribose) Polymerase Inhibition in Patients with Breast Cancer and BRCA 1 and 2 Mutations

Yolanda Jerez et al. Drugs. 2020 Feb.

Abstract

The poly-(ADP-ribose) polymerase (PARP) inhibitors olaparib and talazoparib, have recently been approved for use in patients with metastatic breast cancer (BC) and germline BRCA 1 or 2 mutations due to improved progression-free survival compared to chemotherapy. An increasing number of clinical trials are evaluating the role of PARP inhibitors (PARPi) in BC, alone and in combination with other therapies (including immunotherapy), as well as in earlier stages of the disease. This review describes the unique mechanism of action of these drugs and puts into clinical context the results of pivotal clinical trials. We also discuss the future development of PARPi in BC, their potential combination with other strategies, including chemotherapy and immune-checkpoint inhibitors, and the impact of these treatments in current genetic counselling.

PubMed Disclaimer

References

    1. Cancer Treat Rev. 2018 Jul;68:62-68 - PubMed
    1. N Engl J Med. 2018 Nov 29;379(22):2108-2121 - PubMed
    1. Cancer Manag Res. 2019 Mar 22;11:2321-2337 - PubMed
    1. Lancet Oncol. 2011 Sep;12(9):852-61 - PubMed
    1. J Clin Med. 2019 Mar 30;8(4): - PubMed

LinkOut - more resources